Your search history is turned on.
Date: March 1, 2024 Jurisdictions: British Columbia, Ontario
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the Interim Filings) of Portage Biotech Inc. (the Issuer) for the interim period ended December 31, 20...
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ian B. Walters, Chief Executive Officer of Portage Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the Interim Filings) of Portage Biotech Inc. (the Issuer) for the interim period ended December 31...
PORTAGE BIOTECH INC. THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 MANAGEMENTS DISCUSSION AND ANALYSIS Prepared as of February 28, 2024 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary...
Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Nine Months Ended December 31, 2023 (Unaudited Prepared by Management as of February 28, 2024) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim F...
Date: September 29, 2023 Jurisdictions: British Columbia, Ontario
Portage Biotech Announces $6.0 Million Registered Direct Offering WESTPORT, Conn., Sept. 29, 2023 -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,1...
Date: September 8, 2023 Jurisdictions: British Columbia, Ontario
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the Interim Filings) of Portage Biotech Inc. (the Issuer) for the interim period ended June 30, 2023....
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ian B. Walters, Chief Executive Officer of Portage Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the Interim Filings) of Portage Biotech Inc. (the Issuer) for the interim period ended June 30, 2...
file:///C:/Users/pq385697/Notified/DM%20File%20Repository%20-%2 PORTAGE BIOTECH INC. THREE MONTHS ENDED JUNE 30, 2023 MANAGEMENTS DISCUSSION AND ANALYSIS Prepared as of August 29, 2023 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares 8 Business Environment ...
file:///C:/Users/pq385697/Notified/DM%20File%20Repository%20-%2 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three Months Ended June 30, 2023 (Unaudited Prepared by Management as of August 29, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice t...
Date: August 8, 2023 Jurisdictions: Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, WALTERS, Ian, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable ...